Dr. Ali Al-Ghamrawy, Chairman of the EDA, received a high-level delegation from the United States Pharmacopeia (USP), as part of efforts to support technical and regulatory cooperation and to strengthen the pharmaceutical regulatory system in line with international best practices and standards.
The meeting was attended by Dr. Tamer Elhossieny, Vice Chairman of the EDA, The USP delegation included Dr. Alessandro Slama, Regional Vice President and Vice President of Operations; Dr. Zakia El Kordi, Regional Manager for the Middle East and Africa; Dr. Sarah El Hilaly, Senior Manager of Public Policy and Regulatory Affairs and USP Representative for the Eastern Mediterranean and North Africa Region; as well as Eng. Aliaa Saeed Qarain, CEO of Business Development and Co-Founder of Almasat Life Sciences.
The meeting focused on several technical and regulatory matters, in addition to reviewing the presentation delivered by USP, highlighting its technical and regulatory advantages that support the Authority’s work in the areas of quality assurance and pharmaceutical oversight.
Dr. Al-Ghamrawy emphasized the importance of expanding frameworks of cooperation with international reference institutions, noting that the partnership with USP represents significant added value to the EDA's institutional capacities, contributing to the development of the regulatory framework and enhancing quality assurance efficiency in line with global standards.
He added that the EDA operates under an integrated vision aimed at enhancing the alignment of legislation and regulatory controls with international references, thereby supporting the competitiveness of the Egyptian pharmaceutical industry at both the regional and international levels, and ensuring the availability of safe, effective, and high-quality pharmaceutical products for Egyptian citizens.
He further stated that this collaboration marks a vital step in the sustainable development of the regulatory system and reflects international confidence in the EDA's growing regulatory role.
Consequently, a Letter of Agreement was signed between the two sides under the Regulatory Agency Preferential Access Program, aimed at strengthening technical and regulatory cooperation and supporting the exchange of expertise and capacity building.
For their part, members of the USP delegation expressed their appreciation for the pivotal role played by the EDA in developing the pharmaceutical system, commending the tangible progress achieved by the Authority in the areas of institutional governance and the application of international standards.
These meetings reflect the EDA’s commitment to strengthening its international relations and developing strategic partnerships in a manner that contributes to achieving sustainable development goals and enhancing the efficiency of the pharmaceutical sector in Egypt.